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The prosthesis was retained for 6 months. Further attempts at refining keratoprostheses were associated with a high rate of failure with tissue necrosis, leakage, infection and extrusion of the device. 2 Interest in keratoprostheses waned when Zirm performed the first successful human-to-human corneal graft in 1906. However, there was renewed interest when it was found during World War II that polymethylmethacrylate (PMMA) splinters embedded in the corneae of pilots were well tolerated.
Many KPros have come and gone. The two that have withstood the test of time and remain in widespread use are the Boston type 1 KPro and the osteo-odontokeratoprosthesis (OOKP). The Boston type 1 KPro is used for eyes with an adequate tear film and an intact blink mechanism. The OOKP, introduced by Strampelli 3 and modified by Falcinelli, 4 is used in eyes that are dry or have defective lids or impaired blinking. Both devices are called 'hard keratoprostheses' and consist of basically an optic and a retention system. The introduction of the AlphaCor coreand-skirt hydrogel KPro paved the way for 'soft keratoprostheses' which more closely resemble a human cornea. The AlphaCor is a flexible hydrogel-based device made from poly-2-hydoxyethyl methacrylate (PHEMA). It has a 1-year retention rate of 80%. 5 This demonstrated that a full-thickness artificial cornea can be supported within the corneal stroma through the in-growth of fibroblasts and biointegration with the surrounding corneal stroma, and without the need for further mechanical attachments.
The AlphaCor was associated with several shortcomings. It did not support surface epithelialisation; there were undesirable optical effects from the presence of a meniscus of tears from the optic being sunken under an annulus of anterior corneal lamella; the soft optic buckled and was sometimes subject to depositions; and more significantly, the anterior corneal lamella continued to melt in many cases, with the resultant enlargement of the anterior central opening and the exposure/ extrusion of the device. Many important lessons have been learnt from the AlphaCor.
The ideal soft KPro would have an optic that would provide durable clarity and should integrate easily and quickly with the surrounding host tissues ultimately to become an integral part of the eye. The PMMA surface of 'hard KPros' does not support epithelial growth, and indeed epithelial overgrowth is not wanted. However, soft KPros should allow and support surface epithelialisation on the anterior surface to minimise the chance of tissue necrosis, melt, leak and infection. The surface epithelialisation should be complete, even, and of a good quality in order to provide a good optical surface.
To help with bio-integration and encourage the adherence of epithelial cells, recent work with soft KPros has included: mixing different hydrogel polymers to create copolymers that harness the beneficial properties of individual polymers, tethering biomolecules to copolymers, 6 coating polyvinyl alcohol hydrogels with a biological matrix material, 7 crosslinking collagen with different copolymers 8e11 and creating structures of two or more interpenetrating polymer networks (IPN) to endow the resulting IPN with the beneficial properties of both networks while compensating for some of their less desirable properties. 12e14 In this month's issue, Karkhaneh et al (see page 405) explores the migration and retention of epithelial cells onto polydimethylsiloxane (PDMS) films that had undergone surface modification with the hydrophilic polymers of PHEMA and acrylic acid and type 1 collagen linking. 15 Corneal epithelial cells persisted on this modified surface for 3 months.
In terms of completely synthesising an artificial cornea for transplantation, tissue engineering and cell culture are exciting technologies. Tissue engineering would function to provide the scaffold of the artificial cornea, while cell cultures will provide the ex vivo expansion of self or allo-stem cells. Work is ongoing on a collagen-based corneal substitute. However, this 'collagen construct' is still at an experimental stage. 13 16 In the future, there will most likely be a small range of corneal substitutes ranging from prostheses to tissue-engineered matrix substitutes that would be manufactured for different clinical indications. The tissue-engineered matrices would either be produced as sterile acellular matrices or be complete with functional cells, ready for implantation.
While it is likely that we will eventually be able to manufacture artificial corneae for penetrating keratoplasty, it is unlikely that these artificial corneae or soft KPros would match the longevity of the hard KPros when implanted in hostile ocular surface environments. Therefore, for the future, it is likely that the OOKP will retain its importance as the procedure of choice with dry eyes or eyes with impaired blinking, while the Boston Type 1 KPro will be used with wet blinking eyes.
The OOKP procedure will evolve to utilise a lamina made of synthetic materials that would allow the integration of buccal mucous membrane but be more resistant to resorption. The patient's buccal mucous membrane graft would still need to be harvested to be used as a protective covering for the lamina. The Boston Type 1 KPro will likely be refined with new materials or hybrids, while the Boston Type 2 will eventually merge with the OOKP, morphing into an epicorneal device with buccal mucous membrane cover.
The evolution of newer KPros will improve on the success of the current hard KPros and will also take us ever closer to
Online First
Want the latest articles? Why not try Online First, which publishes articles three weeks after acceptance, months ahead of publication in a printed journal issue. To view these and all of our online content, visit bjo.bmj.com.
